



NEWS RELEASE

## **RaQualia Receives an Allowance for an Acid Pump Antagonist Substance Patent**

**March 25, 2013** - RaQualia Pharma Inc. today announced that the company received an allowance\* for an Acid Pump Antagonist (APA) substance patent in U.S.A. (Application Number: 12/442,277).

RaQualia has substance patent rights for the program in more than ten countries including Japan, Europe, Korea and China. This allowance ensures that our intellectual property rights will be strengthened in U.S.A.

RaQualia licensed APA project for East Asian rights to CJ CheilJedang (headquartered in Seoul, South Korea; CEO Kim Chul-ha) in September 2010, which is presently pursuing development in Korea.

This APA has a different mechanism of action for suppressing gastric acid secretion than the proton pump inhibitor (PPI), the current therapy of choice for treating gastro-esophageal reflux disease (GERD). We anticipate APA will demonstrate faster and sustained gastric acid reduction when compared with PPI. APA is expected to improve GERD symptom control that is inadequately addressed by PPI therapy. Moreover, it will have a possibility of being a new treatment for other acid-related digestive diseases like peptic ulcer.

RaQualia will continue its efforts to secure patents for APA in other regions, while it strengthens the licensing activities globally.

This step has little impact on RaQualia's Business Forecast issued on February 15, 2013.

\*A patent allowance is an evaluation by a country's patent office that a patent application merits being granted a patent. After the patent is allowed and the fee paid, it is registered and the patent is issued in the relevant country.

####